SERIOUS INFECTION AND ASSOCIATED RISK FACTORS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB

被引：2
|
作者：
Winthrop, K. L. [1 ]
Genovese, M. C. [2 ]
Harigai, M. [3 ]
Chen, L. [4 ]
Dickson, C. L. [4 ]
Hyslop, D. L. [4 ]
Nishikawa, A. [5 ]
Bradley, J. D. [4 ]
Dougados, M. [6 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Stanford Univ, Palo Alto, CA 94304 USA
[3] Tokyo Womens Med Univ, Tokyo, Japan
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Lilly Japan KK, Kobe, Hyogo, Japan
[6] Paris Descartes Univ, Paris, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.1312
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0248
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [1] Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib
    Winthrop, Kevin L.
    Lindsey, Stephen
    Weinblatt, Michael
    Takeuchi, Tsutomu
    Hyslop, David
    Issa, Maher
    Chen, Lei
    Bradley, John
    Dickson, Christina
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] THE RISK FACTORS OF SERIOUS INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hasegawa, E.
    Kobayashi, D.
    Ito, S.
    Narita, I.
    Nakazono, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1061 - 1061
  • [3] Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
    Fleischmann, Roy
    Alam, Jahangir
    Arora, Vipin
    Bradley, John D.
    Schlichting, Douglas E.
    Muram, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib
    Valor-Mendez, Larissa
    Manger, Bernhard
    Schett, Georg
    Kleyer, Arnd
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (10): : 980 - 983
  • [5] Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide
    Yoo, Han-Gyul
    Yu, Hea Min
    Jun, Jeon Byung
    Jeon, Hyun-Soon
    Yoo, Wan-Hee
    MODERN RHEUMATOLOGY, 2013, 23 (04) : 709 - 715
  • [6] Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis
    Dabal, Tracey D.
    Haltom, Matthew B.
    Patel, Puja P.
    Son, Christine K.
    Joglekar, Kiran P.
    Groeschell, Charles M.
    Chumpia, Mason M.
    Kamal, Sehrish F.
    Seth, Ankur
    Jackson, Christopher D.
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (05) : 288 - 292
  • [7] Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease
    Jorge A. Zamora-Legoff
    Megan L. Krause
    Cynthia S. Crowson
    Jay H. Ryu
    Eric L. Matteson
    Clinical Rheumatology, 2016, 35 : 2585 - 2589
  • [8] Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease
    Zamora-Legoff, Jorge A.
    Krause, Megan L.
    Crowson, Cynthia S.
    Ryu, Jay H.
    Matteson, Eric L.
    CLINICAL RHEUMATOLOGY, 2016, 35 (10) : 2585 - 2589
  • [9] Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
    Thudium, Christian S.
    Bay-Jensen, Anne C.
    Cahya, Suntara
    Dow, Ernst R.
    Karsdal, Morten A.
    Koch, Alisa E.
    Zhang, Wenling
    Benschop, Robert J.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [10] Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
    Morel, Jacques
    Constantin, Arnaud
    Baron, Gabriel
    Dernis, Emmanuelle
    Flipo, Rene Marc
    Rist, Stephanie
    Combe, Bernard
    Gottenberg, Jacques Eric
    Schaeverbeke, Thierry
    Soubrier, Martin
    Vittecoq, Olivier
    Dougados, Maxime
    Saraux, Alain
    Mariette, Xavier
    Ravaud, Philippe
    Sibilia, Jean
    RHEUMATOLOGY, 2017, 56 (10) : 1746 - 1754
12345